BlueOrange Asset Management November results
Our weighted average return in November was –0.36%, bringing our year-to-date return to +15.26%.
Many of our favoured sectors performed poorly in November – emerging market bonds sold off, biotech was weak and base metals miners underperformed. Thankfully, our asset allocations and security selection allowed us to preserve capital in our portfolios.
Earlier in the month, I attended an investment conference in Berlin and was taken aback by the amount of construction going on in the city. My perceptions of the German economic zeitgeist were confirmed later on in the month when I heard of an actual case of a commercial lease in Berlin being renewed at a 40% increase to its previous level. Unsurprisingly, Germany reported impressive GDP growth of 2.8% versus an estimate of 2.3%. Clearly low rates in Europe are having the desired effect in its largest economy. Moreover, the Eurozone manufacturing Purchasing Managers’ Index (PMI) hit a new record high of 60.1, which is consistent with a growth rate of more than 3%. Not so long ago Europe was petrified of deflation and interest rates were below 0%. Now the stage has been set for what could be considerable inflation. It remains to be seen how the ECB will navigate this new environment, but we will be avoiding investment grade, long duration European bonds for the foreseeable future.
We were not particularly active in our portfolios last month but took advantage of weakness in European financials to buy back positions that we sold at higher levels. Unlike other asset managers that try to play around certain benchmarks, we only buy and hold what we like and what we believe will generate superior returns for our clients. This provides us with two major advantages over other asset managers: 1) we can take profits when we see fit and not be bothered if ‘underweight’ positions perform well; 2) it encourages us to seek out opportunities before they appear on other managers’ radars (this is where real alpha is generated).
Last month provided a very good example of us seeking out opportunities before they appear on other managers’ screens: we purchased Canadian medical marijuana stocks in our aggressive portfolios. Canada will be legalizing recreational marijuana on July 1st of next year, and the battle to meet consumer demand is raging. This sector has been on our radar for some time now, but we deemed a significant number of successful secondary financings in the space to be a tipping point for institutional investor acceptance. We made gains of over 40% in one month, took profits and continue to evaluate which companies will emerge as the true leaders in this space, as well as which of their competitors they might be buying up along the way.
Please feel free to contact us email@example.com if you would like to hear more about our investment strategies.
On the behalf our portfolio management team, I thank you for your continued trust and support!
Important Legal Information
Nothing contained herein constitutes an offer, solicitation or recommendation regarding any investment product or service, or the offer to sell or the solicitation of an offer to buy any financial instrument; nor shall any such services be provided, or financial instruments be offered or sold, in any jurisdiction in which such an offer, solicitation, provision or sale would be unlawful. All content is subject to applicable statutes and regulations. Any potential investor should satisfy oneself that an investment in any product and/or service mentioned in this material is permissible under the rules and regulations of his or her domicile. This material is not directed to any person in any jurisdiction where (by reason of that person's nationality, residence or otherwise) the availability of the material is prohibited.
The information provided is for reference only and investors should determine for themselves whether a particular service or product is suitable and appropriate for their investment needs or should seek such professional advice for their particular situation. Please refer to offering documents for further information concerning specific products.
Certain statements contained herein may be statements of future expectations and other forward-looking statements that are based on current views and assumptions of AS BlueOrange Bank and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential, or continue” and similar expressions identify forward-looking statements. BlueOrange assumes no obligation to update any forward-looking information contained herein.
Past performance is no guarantee of future results. Investing in the financial markets is subject to certain risks including market, interest-rate, issuer, credit, and inflation risk. Financial instruments may appreciate or depreciate in price owing to conditions, whether real or apparent, in a given market, economy or industry. The value of investments, and the income from them, can go down as well as up, and you may not recover the amount of your original investment. Where investments involve currency exposure, changes in rates of exchange may cause the value of the investment to go up or down. Any tax benefits referred to on this material are subject to change and their availability and value will depend on your individual circumstance.
Although BlueOrange has taken reasonable care to ensure that the information contained within this material is accurate, no representation or warranty (including liability towards third parties), expressed or implied, is made as to its accuracy, reliability or completeness by BlueOrange. Opinions and any other contents of the material are provided by BlueOrange for personal use and for tentative reference only. Nothing contained on this material constitutes investment, legal, tax or other advice and is not to be relied on in making an investment or other decision.
© 2017 AS BlueOrange Bank. All rights reserved.